Financial News

New York State Attorney General Letitia James inked a settlement with Emergent under which the company will pay $900,000 in penalties.

Topics Regulatory Compliance

AstraZeneca PLC (NASDAQ:AZN) Emerges as a Quality Investment Candidate ↗

January 20, 2026

Via Chartmill

Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All ↗

January 19, 2026

Via MarketBeat

Topics ETFs

Why Did EBS Stock Fall 13% Today? ↗

January 15, 2026

Topics Law Enforcement Lawsuit

AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline ↗

January 13, 2026

The Newest Stock in the Nasdaq-100 Soared 549,000% Since Its IPO, and It's Still a Buy Right Now, According to Wall Street (Hint: Not Strictly a Tech Company) ↗

Topics Artificial Intelligence

January 15, 2026

Shares of this household name outperformed the broader market indexes in 2025, and that could be more to come.

Retail’s Tech Coronation: Walmart Joins the Nasdaq-100 Following Historic Exchange Pivot

Topics Artificial Intelligence Bankruptcy Initial Public Offering

Records, Subpoenas, and $4,600 Gold ↗

January 13, 2026

Via Chartmill

Topics Law Enforcement

January 12, 2026

In a move that signals the definitive blurring of the lines between traditional retail and big tech, Walmart Inc. (Nasdaq: WMT) is officially scheduled to join the Nasdaq-100 Index prior to the market...

Walmart Inc. (NYSE: WMT) reached an unprecedented milestone on Monday, January 12, 2026, with its stock price closing at an all-time high of $117.48. The retail giant’s surge comes amidst a broader...

Topics Artificial Intelligence ETFs Economy

Walmart (WMT) Hits All-Time High as Investors Pivot to Consumer Defensive Giants

January 12, 2026

Cashing In at the Peak: Olema Pharmaceuticals Insiders Sell $8 Million in Stock After 300% Surge

Topics Artificial Intelligence Economy Supply Chain

January 09, 2026

Olema Pharmaceuticals (NASDAQ:OLMA) has become the latest focal point of biotech volatility and executive opportunism. Following a staggering 300% surge in its share price over the past year—fueled by...

AMD Ignites the ‘Yotta-Scale’ Era: Unveiling the Instinct MI400 and Helios AI Infrastructure at CES 2026

January 08, 2026

LAS VEGAS — In a landmark keynote that has redefined the trajectory of high-performance computing, Advanced Micro Devices, Inc. (NASDAQ:AMD) Chair and CEO Dr. Lisa Su took the stage at CES 2026 to...

Via TokenRing AI

Topics Artificial Intelligence Economy

Momentum in Healthcare and Banking to Persist in 2026 as AstraZeneca and Citigroup Lead the Charge

January 02, 2026

As the global markets open for the first week of 2026, a clear narrative has emerged: the "recovery plays" of 2025 have officially transformed into the "expansion leaders" of the new year. Following a...

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

Topics Artificial Intelligence Economy Initial Public Offering

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

This rising star in quantum computing is a high-risk but potentially high-reward play.

Topics Economy Intellectual Property World Trade

Is IonQ Stock a Buy Now? ↗

December 30, 2025

MIchaelAaron Flicker is the co-author of "Hacking The Human Mind: The Behavioral Science Secrets Behind 17 of the World's Best Brands."

The Motley Fool Interviews MichaelAaron Flicker: Hacking the Human Mind ↗

December 29, 2025

AstraZeneca (AZN) shows a top technical rating and a high-quality consolidation pattern, signaling a potential breakout opportunity for technical traders.

AstraZeneca (NASDAQ:AZN) Shows Strong Technical Setup for Potential Breakout ↗

December 23, 2025

Via Chartmill

The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth

December 22, 2025

As of today, December 22, 2025, Pfizer Inc. (NYSE: PFE) stands as a case study in corporate reinvention and the brutal reality of the post-pandemic "hangover." Once the darling of the global healthcare...

Via PredictStreet

Topics Economy Intellectual Property

Trump Strikes New Drug-Price Deals With Roche, Novartis, Merck And Other Pharma Giants ↗

December 19, 2025

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

The stocks listed here trade at forward earnings multiples of less than 18.

Topics Government World Trade

3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now ↗

December 18, 2025

Novartis US Stock Rises On Reports Of White House Pricing Deal Due Friday — Roche Also In Talks ↗

December 17, 2025

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

The New Year is shaping up to be an important one for this quantum computing stock.

Topics Government World Trade

What to Watch With IonQ Stock in 2026 ↗

December 11, 2025

The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.

Topics Artificial Intelligence

US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report ↗

December 01, 2025

Biotech Bull ETF Surges To 20-Month High: Analysts Say Medicare’s Drug-Pricing Blow Is Softer Than Feared ↗

Topics World Trade

November 27, 2025

Pricing updates for major therapies from Novo Nordisk, Teva, AbbVie, and others eased sector worries.

Novo Nordisk stock jumped Wednesday on a lighter-than-feared discount for Ozempic and Wegovy under the IRA.

Topics ETFs

Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗

November 26, 2025

Via Investor's Business Daily

Topics Economy Government

AstraZeneca PLC-SPONS ADR (NASDAQ:AZN) Passes Key Quality Investing Screen for Long-Term Growth ↗

November 25, 2025

AstraZeneca (AZN) is a top-quality stock for long-term investors, showing strong revenue growth, high profitability, and solid cash flow generation.

Via Chartmill

Why AstraZeneca Stock Bumped Higher Today ↗

November 21, 2025

The company is wasting little time figuring out the particulars of a sweeping capital investment program.

AstraZeneca receives FDA approval for Koselugo to treat adults with NF1 and inoperable plexiform neurofibromas, backed by strong Phase 3 data.

Topics Artificial Intelligence

FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio ↗

November 20, 2025

Via Benzinga

Where Will IonQ Be in 10 Years? ↗

November 20, 2025

A lot can happen for this quantum computing leader over the next decade.

Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.

Johnson & Johnson Inks A $3.05 Billion Deal In Cancer Treatment ↗

November 17, 2025

Via Investor's Business Daily

IonQ (IONQ) Surges on Strong Revenue Outlook and Insider Confidence Amidst Quantum Computing Race

November 14, 2025

November 14, 2025 – Quantum computing pioneer IonQ (NYSE: IONQ) recently captured significant market attention, with its stock experiencing a notable 3.6% gain on November 5, 2025, driven by an...